Folien_Prof.Werner_Internet.ppt - Boehringer Ingelheim Pharma ...

More documents

Recommendations

Info

History of Modern Biotechnology at BI VIENNA BIBERACH 1963: Start of research activities with Interferon a, ß, γ, ω 1982: Cooperation with Genentech, USA: Actilyse ®, Beromun ®, Imukin ® 1985: Major investment into microorganism fermentation plant, Vienna 1986: Major investment into mammalian cell culture fermentation plant, Biberach 1991: Cooperation with IDEC Pharm. Corp. / Zenyaku Kogyo: Specifid ® 1992: Cooperation with NeoRx Corporation: Verluma ® 1998: Strategic decision to expand into Contract Manufacturing Business 2003: Major investment into mammalian cell culture plant, Biberach 2004: Major investment into microorganism plant, Vienna 2
Biopharmaceutical Structures Microbial synthesis of low molecular weight non glycosylated therapeutic proteins Insulin 6 kD Small molecules 0,6 kD Nanobody 15 kD Mammalian cell culture synthesis of high molecular weight complex and glycosylated therapeutic proteins Tissue Plasminogen Activator 65 kD Monoclonal Antibody 150 kD 3
Page 1: Please enter title of conference, m
Page 5 and 6: Boehringer Ingelheim Pharma GmbH &
Page 7 and 8: Process Sciences and Manufacturing:
Page 9 and 10: Titer [g/L] Mammalian Cell Culture
Page 11 and 12: Increased Productivity in Upstream
Page 13 and 14: 600 500 400 300 200 100 0 35 Net Sa
Page 15: BI Clients out of Top 25 Corporatio

Folien_Prof.Werner_Internet.ppt - Boehringer Ingelheim Pharma ...

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?